Loading Events

« All Events

  • This event has passed.

Discussion on Master Protocols for Evaluation of Candidate COVID-19 Therapeutics

November 22, 2021, 5:00 pm PST

The instructional team from PHW236A: Regulatory Science, Drug Development, and Public Health are extending an invitation to the entire Berkeley Public Health community to attend the course’s online Journal Club session on Master Protocols for Evaluation of Candidate COVID-19 Therapeutics. The Journal Club is scheduled for Monday, November 22 at 5 pm PST.

In their recent article, the Therapeutics-Clinical Working Group members of the Accelerating COVID-19 Therapeutics Interventions and Vaccines (ACTIV) public-private partnership describe the process by which nine master protocols were designed, developed, and launched between 14 April 2020 and 31 May 2021 to allow for the coordinated and efficient evaluation of multiple investigational therapeutic agents for COVID-19.

Two members of the Therapeutics-Clinical Working Group, including Dr. Judith S. Currier and Dr. Sarah Read will participate in the Journal Club session.

About the authors:

Dr. Judith S. Currier is Professor of Medicine and Division Chief for Infectious Diseases at UCLA’s David Geffen School of Medicine, Associate Director of the UCLA Center for Clinical AIDS Research and Education (CARE), and Chair of the AIDS Clinical Trial Group (ACTG). Dr. Currier is a member of the ACTIV Therapeutics-Clinical Working Group.

Dr. Sarah Read is an infectious disease physician and Deputy Director of Therapeutics Research for the Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Dr. Read is Co-Chair of the ACTIV Therapeutics-Clinical Working Group.

Zoom link


Online – Virtual Event


Michelle Ruiz, UC Berkeley School of Public Health